I am not the answer man. But shorts just do leave. Retail shorts bail fairly fast, but funds with a billion or so at their disposal, simply short more, just as long funds buy more. When the tipping point gets reached, one or the other runs. What has worked for a few months for the funds is cover at low 8's, short in the 9's, take the cash buy gild, etc., a paired trade. TIME is running out on that play, not 100% positive they can be nudged out, but the writing is getting burned into the wall.
The problem they have is NO shares to cover with, they will short more, cover some, hoping retail, THEIR SAVIOR, sells. Today they ran it down hoping tons of retail would sell, some did, not enough. They ran it up hoping to get enough profit takers to cover a little, not enough sold. They are in a pickle, know it, and will manipulate to cover, as today's action showed. It will take only one big house upgrading to spike this puppy a couple of bucks, a GS, C, etc., I expect it, but could be wrong.
We have 2016 as a time frame, their's is no different. They have played this like a fiddle for months, as the float dwindled, the rope is indeed short.
So your question is who is doing all the selling? It is likely the same fund doing all the BUYING. They can do that. Ever buy a secondary at x, to be completed in three days. Ever notice the secondary is within pennies of the X price about 95% of the time, we have no control, funds can move a stock within a dime of their target unless opposed buy a big buyer or seller they did not see, and only after their funds are used up TEMPORARILY.
I saw Anne Opko first, you can eye her cousin Calamity opko, if you like, or maybe Katie Elder opko but Anne Opko is spoken for. SSHHH, it is a secret.
Waiting on that one big broker, GS, JPM, MER, C to upgrade with an 18 price target, lol. could happen sooner than later.
Thanks you too, and your family. My take is EVERYTHING at opko is unfolding as Frost laid it out. Not sure on 4k, but hope getting in guidelines gives it a boost in sales. NDA Rayaldee in under 2 weeks, 4k Latin America also. My price target is still a meager 30 by end of 2016.
It based for 6 straight months, time to get in a new range, if you did not buy in the 8's, you could easily miss the 9's if you wait too long.
before going public.
Frost has take longer breaks from buying, and then resumed with no news being released. True, the stock tends to go up during those dry periods, shorts do look over their shoulder at those times. The majority of the shorts will find NO shares to cover with, matter of when, not if that happens. Why you think they have resident paid bashers? It is known where the shares are. Frost owns X, funds own X, Retail is their only hope, but the shortage of shares to cover is 20 million or in that range. So in time, we get a squeeze based on 20-25 million with no sellers.
Well when did you think opk would be profitable? Obviously this BIG BIG cash infusion will close, but might not be accounted for as the .63 earnings it really is. My timeline has been 2016, based on Rayaldee 2015, and Rolipitant 2015 approval. 2016 will be great, 2017 MONSTER year IMHO. NO DOUBT opk will have over 2b in 2017.
Total sales 3b, excuse me, 1.5b each companies share of the pie. 1.5 To Opko, 1.5 to pfe.
pfe WITH many many pharmacies selling Genotropin the drug generated Genotropin generated for us at pfe " revenues of $772 million in 2013." If we partner with OPKO, eliminating Novo, and all the competition because we have the best drug out there, we and Opko can do roughly 1.5 BILLION in sales year one, and grow from there.
When a stock that’s relatively stable suddenly sees an 8.3% one-day spike – and on volume that’s over five times higher than its regular daily average – it’s time to pay attention.
That’s precisely what happened to biopharmaceutical and diagnostics company, Opko Health (OPK), on Monday.
It’s been an okay year for the Miami-based firm, with shares up over 8% year to date.
But an 8.3% one-day spike is an anomaly. So is the sudden rise warranted?
Thanks to a recent deal with Pfizer (PFE), it might be…
Pfizer-Fueled Gains on the Horizon
On the plus side, Opko boasts very low debt and a current ratio of 2.12, which shows that the company has the ability to meet its short-term liquidity needs.
But here’s a bigger reason why investors should remain bullish…
Opko and Pfizer recently announced that they’ve entered into a global agreement for the development and commercialization of Opko’s long-acting hGH-CTP therapy for the treatment of growth hormone deficiency. The treatment primarily targets growth failure in children who do not show catch-up growth by two years of age.
According to the agreement, Opko will receive an upfront payment of $295 million and is eligible to receive an additional $275 million upon the achievement of specific milestones.
In return, Pfizer will receive exclusive licensing rights for the commercialization of HGH-CPT worldwide.
The benefit for Opko shareholders here is obvious: By luring Pfizer’s expertise in realizing the vast potential for hGH-CTP, the alliance could transform Opko’s fortunes and ignite the shares.
Especially since the market value for the therapy is over $3 billion.
You see, hGH-CTP has the potential to be the best-in-class, long-acting growth human growth hormon, immediately accretive to opko's bottom line.
Talk about understating things, hello, they are PAYING over 1/2 a billion to join the OPKO team.
We knew from the last earnings and Oppenheimer conferences a deal was in the works, but this is WAY better than ANYONE expected. Own half of the pfe hgh franchise, global leader, get a half billion cash for the honor, turn immediate 90 million profit on prolar deal. Geesh, Uncle Phil is a genius.
The cash PFE is handing opk makes the prolar deal 90 million profit. The beauty is opko still owns half the drug, and gets royalties on a pfe drug too boot. In other words opko owns HALF of pfe hgh franchise, which they are the world leader in.
Smart move, gaining revenue from a drug OPKO does not own, but PFE thought it worth it to gain the OPKO hgh.
Cramer was drooling over the pfe deal, so I am betting he called Frost.
OPKO Health deal with Pfizer removes financing overhang, says Ladenburg
Ladenburg views the agreement OPKO Health (OPK) signed with Pfizer (PFE) as a significant positive catalyst since the company is partnering with an established leader in short-acting hGH and because the large upfront payment removes near-term financing needs as an overhang on the stock. The firm reiterates its Buy rating and $14.50 price target on OPKO, but said it will re-examine its projections after the deal closes.
NO shares for sale, guess EVERY one is canceling sell orders making shorty pay 11-12 is in the cards.
this cash right bio.